Skip to main content

Drug Interactions between fenfluramine and tryptophan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

fenfluramine tryptophan

Applies to: fenfluramine and tryptophan

GENERALLY AVOID: Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.

MANAGEMENT: The concomitant use of serotonin reuptake inhibitors and tryptophan should be avoided.

References

  1. (2001) "Product Information. Zoloft (sertraline)." Roerig Division
  2. (2001) "Product Information. Prozac (fluoxetine)." Dista Products Company
  3. (2001) "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories
  4. (2001) "Product Information. Paxil (paroxetine)." GlaxoSmithKline
  5. (2001) "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc
  6. (2001) "Product Information. Celexa (citalopram)." Forest Pharmaceuticals
  7. (2002) "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals
  8. (2004) "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company
  9. (2008) "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories
  10. (2009) "Product Information. Savella (milnacipran)." Forest Pharmaceuticals
  11. (2009) "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals
  12. (2011) "Product Information. Viibryd (vilazodone)." Trovis Pharmaceuticals LLC
  13. (2013) "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals
  14. (2013) "Product Information. Brintellix (vortioxetine)." Takeda Pharmaceuticals America
View all 14 references

Switch to consumer interaction data

Drug and food interactions

Moderate

fenfluramine food

Applies to: fenfluramine

GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.

MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  3. (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer